Mammaprint
The MammaPrint® test measures the level of activity of 70 genes in a sample of surgically-removed breast cancer tissue. It produces a score that determines whether the patient is at low risk or high risk for spread of the cancer within the next five to ten years. Patients whose tissues are eligible for MammaPrint®
analysis must be younger than 61 years of age, have stage I or II invasive breast cancer that is estrogen-receptor positive or estrogen-receptor negative, and have negative lymph nodes.
MammaPrint® is performed on fresh tissue rather than formalin-fixed, paraffin-embedded tissue as is Oncotype DX.